AXGN vs ANIK

For growth investors, AxoGen, Inc.

(AXGN) is the stronger pick with 20. 2% revenue growth year-over-year, versus -5. 9% for Anika Therapeutics, Inc. (ANIK). Analysts rate AxoGen, Inc. (AXGN) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AxoGen, Inc.

(AXGN) delivered a total return of +84. 7%, compared to -63. 9% for Anika Therapeutics, Inc. (ANIK). Over 10 years, the gap is even starker: AXGN returned +647. 2% versus ANIK's -65. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AxoGen, Inc.

(AXGN) is the lower-risk stock at 0. 90β versus Anika Therapeutics, Inc. 's 1. 14β — meaning ANIK is approximately 27% more volatile than AXGN relative to the S&P 500. On balance sheet safety, AxoGen, Inc. (AXGN) carries a lower debt/equity ratio of 15% versus 17% for Anika Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AxoGen, Inc.

(AXGN) is pulling ahead at 20. 2% versus -5. 9% for Anika Therapeutics, Inc. (ANIK). On earnings-per-share growth, the picture is similar: Anika Therapeutics, Inc. grew EPS 80. 2% year-over-year, compared to -47. 8% for AxoGen, Inc.. Over a 3-year CAGR, AXGN leads at 17. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AxoGen, Inc.

(AXGN) is the more profitable company, earning -7. 0% net margin versus -9. 6% for Anika Therapeutics, Inc. — meaning it keeps -7. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AXGN leads at -3. 5% versus -9. 8% for ANIK. At the gross margin level — before operating expenses — AXGN leads at 74. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, AxoGen, Inc.

(AXGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), +647. 2% 10Y return). Both have compounded well over 10 years (AXGN: +647. 2%, ANIK: -65. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AXGN is a small-cap high-growth stock; ANIK is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.